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1. Introduction 
In the past few years, high throughput technologies, such as gene expression microarrays 
and genotyping techniques, have provided efficient ways to measure gene expression levels 
and genotype variation on a genome-wide scale [Schena et al., 1995; Howell et al., 1999]. 
Various approaches have been proposed to analyse gene expression data and genotype 
variation data, in order to discover the complex network of biochemical processes of 
complex diseases such as chronic fatigue syndrome (CFS) [Presson et al., 2008]. In the 
analysis of gene expression data, for example, the identification of differentially expressed 
genes between two groups has been of great interest, and various statistical tests have been 
conducted [Ghazalpour et al., 2008; Brem et al., 2002; Kang et al., 2008]. In analysing 
genotype variation data, logistic regression has been commonly used to model the 
relationship between binary clinical outcomes and discrete predictors, such as genotypes 
[Henshall & Goddard, 1999; Coffey et al., 2004].  
Despite the availability of different levels of genome-wide data, most studies have been 
based on a separate analysis of single-level data to unravel complex biological 
mechanisms of CFS. Complex diseases such as CFS can be explained at different levels of 
biological mechanisms, including DNA, gene expression and phenotype levels. While 
there is a separate mechanism at each level, the mechanisms at different levels are closely 
related to each other in initiating and influencing CFS. Furthermore, CFS is expected to 
have complex etiology, which involves the action of many genes in addition to dynamic 
gene-environment interactions [Lin et al., 2009]. Therefore, separate analyses of single-
level data have a limitation in identifying and characterizing genes that are associated 
with the susceptibility of CFS. The integration of the different types of data (for example, 
gene expression, genotype variation and clinical outcomes) can provide more 
comprehensive information related to CFS, hence elucidate complex networks of gene 
interactions underlying CFS. 
In this chapter, we provide an overview of the integrated statistical model (ISM) in order to 
characterize CFS, which involves integrating genotype variation data and gene expression 
data. The ISM elucidates the causal relationship between genetic variation, gene expression 
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level and disease. The ISM consists of two steps. The first step is to determine the causal 
relationship. Based on the causal relationship determined at the first step, the second step 
identifies significant gene expression traits of which the effects on disease status or the 
responses to disease status are modified by the specific genotype variation. By applying the 
ISM procedure to a CFS dataset, we identified a list of potential causal genes for CFS, and 
found an evidence for a difference in genetic mechanisms of the etiology between CFS 
patient and control groups.  
Our ISM analyses considering the different levels of data simultaneously, allowed us to 
elucidate disease susceptibility and differentially expressed genes of genetically different 
individuals. Some results even showed that integrating genotype and expression data may 
help the search for new directions for the treatment of CFS that are not being detected by 
using only one type of data. The integrated analysis provided more information than the 
two separate analyses of gene expression data and genotype variation data for 
characterizing CFS that has several possible causes.  
2. An overview of Integrated Statistical Model (ISM) 
2.1 From genotype to phenotype 
In the era of the genome project, the belief came with was that we would answer the 
questions on how the genes function and how they are related to diseases. The genome 
project successfully sequenced DNA of various species, including the human. Not only 
sequencing the genomes, many studies have also identified the gene functions by modifying 
individual genes in several animals and plants. However, many questions remain 
unanswered. We still do not know the functions of numerous genes, whether thay are 
annotated or un-annotated. Especially predicting what genes are associated with disease-
related phenotypic variants is of particular interest and still in vague. The problem is 
complicated, because  
i. most phenotypes of medical interest are complex diseases, i.e., more than one gene or 
environmental effect contributes to the phenotype occurrence, 
ii. the underlying molecular mechanism regulating cellular functions is complicated, 
and 
iii. little genotypic data (or information) of disease-related phenotypes is available. 
High throughput technologies advance for acquiring genome-wide genotyping data of 
many individuals with and without disease phenotypes. It is of a particular interest to 
segregate genotypic difference between disease-affected individuals and controls. The 
variation of genotypes comes from additive and epistatic effects of alleles across multiple 
genes, resulting in many individuals with phenotypes. Some combinations of genotypic 
variants result in enhanced traits, whereas other combinations are deleterious to fitness in 
specific environments. Phenotypic alterations are usually in matters of amount, rather 
than in the presence or absence of a trait. The field of statistical genetics has developed 
various methods and tools to map such quantitative traits to regions of chromosomes. 
These chromosomal regions are known as quantitative trait loci (hereafter QTLs) and are 
described in terms of the percentage of the variation of a trait that can be attributed to 
each region. 
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2.1.1 Quantitative Trait Locus (QTL) 
Quantitative traits refer to the characteristics or phenotypes that are quantitative, i.e., vary in 
degree or continuously, such as height, while dichotomous or discrete traits have two or 
several characteristic values. A QTL is a specific region of DNA that is associated with these 
quantitative phenotypic traits. The number of QTLs that explain the variation in the 
phenotypic trait tells us more about the genetic structure of a specific trait. For example, the 
research related to QTLs could provide further information about the genes that control 
human height. 
2.1.2 xQTL: Various types of QTL mapping 
Microarray technology has elucidated the genetics of gene expression in human 
populations. It has been less successful to identify genes in underlying diseases by using 
molecular profiling tools. Since too many genes have been identified to be associated with 
disease traits, determining and verifying which genes are the true disease-causing genes 
have been difficult. 
Recently, microarray techniques have been combined with genotyping technology to 
facilitate the identification of key drivers of complex diseases. Figure 1 represents this 
approach, treating relative transcript abundances as quantitative traits when segregating 
populations. In this method, chromosomal regions that control the level of expression of a 
particular gene are mapped as expression quantitative trait loci (eQTL). 
This eQTL scheme can be easily extended to other data types, for example, proteome, 
metabolome and phenome. Figure 2 illustrates this extension: protein expression (pQTL), 
relative metabolites abundances (mQTL) and phenotype abundances (phQTL).  
 
Fig. 1. eQTL pipeline. From disease and normal individuals, genotypes and mRNA 
expressions are observed.  
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Fig. 2. A schematic representation of extended xQTL analyses. 
2.2 Integrative analysis 
Fu et al. provided the first system-wide evidence for phenotypic buffering in Arabidopsis [Fu 
et al., 2009]. Their approach consisted of three steps. Step 1 performed QTL mapping for 
transcript, protein, metabolite and phenotypic trait data. Then, Step 2 computed significance 
thresholds for detection of QTL hotspots per level, and finally, Step 3 detected hotspots that 
appeared across multiple levels. In particular, at Step 2 permutation analysis was used to 
compute significance thresholds for detecting QTL hotspots. For each of the 250 
permutations, all > 40,000 traits were analyzed in order to map QTLs and the most 
significant marker for each QTL was stored. The number of significnat QTLs were counted 
over all traits for each marker, and the significant thresholds for hotspot detection per level 
were derived. For system-wide or multiple level QTL hotspots, Step 3 used the observed 
QTL hotspots and permutation analysis to compute significance thresholds for detecting 
QTL hotspots that appeared at multiple levels. Using the results obtained from per-level 
analysis, the markers per level were ranked from the one with the highest number of traits 
mapping to it, to the one with the lowest. Then, a rank-product test was performed to find 
markers that ranked significantly high at multiple levels [Breitling et al., 2004]. For each 
permutated sample, the p-value was computed for the rank-product test at each of the 144 
markers, and a threshold was derived for hotspot detection by the procedure controlling 5% 
of the false discovery rate (FDR) [Benjamini & Hochberg, 1995]. 
Using this approach, 162 recombinant inbred lines (RIL) of Arabidopsis thaliana were profiled 
for variation in transcript, protein and metabolite abundance, and were mapped to QTL for 
40,580 of these molecular traits. Only six QTL hotspots were found which underlied 
variation in 16% of the transcript traits, 25% of the protein traits, 55% of the metabolite traits 
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and 77% of the phenotypic traits for which QTL could be mapped. QTL for 16%, 25%, 55% 
of all transcript, protein and metabolite traits with a QTL, respectively, mapped to the same 
six QTL hot spots, compared to 77% of phenotypic traits. Consequently, screening for 
mutants at the molecular level would increase the probability of identifying new causal loci 
that could not be identified from morphological screens [Boerjan & Vuylsteke, 2009]. 
Using microarrays or massively parallel sequencing it is possible to measure both genetic 
variation and gene expression at genomic level. Hence, eQTL methods allow for studying 
the association of all regions in a genome with the expression of all genes. In this sense it is 
worth re-visiting eQTL in deeper look. 
If the genotype at a certain locus is associated with the phenotype of a certain gene, this DNA 
region might contain a regulator of the target gene expression. It could be any functional 
nucleotide sequences such as protein-coding regions, microRNAs and cis-regulatory DNA 
motifs. The same individuals of a selected population have to be genotyped and phenotyped 
first. Based on the genotyped data (e.g. SNP), selecting markers that are polymorphic in the 
study population is in need. Then, at the heart of every eQTL study is the correlation of 
genotype patterns with expression levels in a genetically diverse population. The simplest 
mapping strategy is to split the population based on the genotypes at a specific marker and 
check if the expression levels of a given gene are significantly different between the two 
groups [Ghazalpour et al., 2008; Brem et al., 2002; Kang et al., 2008].  
There have been many approaches to elucidate the variants affecting phenotypes, for 
example, Lan et al. explored correlation of expression profiles across a genetic dimension, 
namely genotypes segregating in a panel of 60 F2 mice derived from a cross used to explore 
diabetes in obese mice. By combining the correlation results with linkage mapping 
information, they identified regulatory networks, made functinoal predictions for 
uncharacterized genes, and charaterized novel elements of knwon pathways [Lan et al., 
2006]. However, their approach did not provide any information about causality 
relationships among expression profile, genotype and disease.  
The mixture over markers (MOM) model proposed by Kendziorski et al. combinds a 
transcript-based (TB) approach, refering to the repeated application of any single-phenotype 
mapping method to each mRNA transciprt, and a marker-based (MB) approach, refering to 
the repeated application, at each marker, of any method for identifying differnetially 
expressed transciprts [Kendziorski et al., 2006]. They applied two MB approches: an 
empirical Bayes approach and an approach based on the Student’s t-test. The MOM model is 
motivated from the fact that separate tests are conducted for each trascript-marker pair, and 
each measures evidence that the transcipt maps to that marker relative to evidence that it 
maps nowhere. Since a trancript can map to any of various marker locations, the evidence 
that a transcript maps to a particular marker should not be judged relative only to the 
possibility that it maps nowhere, but rather relative to the possibility that it maps nowhere 
or to some other markers. This model was proved useful in improving the specificity of 
eQTL identifications, but used only genotype variation and gene expressino data rather than 
disease status or trait data. 
A gene-set approach based on weighted gene co-expression network analysis (WGCNA) by 
Presson et al. constructs a co-expression network, identifies trait-related modules within the 
network, uses a trait-related genetic marker to prioritize genes within the module, applies 
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an integrated gene screening strategy to identify candidate genes and carries out causality 
testing to verify and/or prioritize results [Presson et al., 2008]. Their work includes steps to 
identify trait-module association and trait-related genetic marker association, but does not 
provide the model-based statistical tests. 
The step-wise approach proposed by Schadt et al. includes i) identifying pair-wise 
relationships among genotype variation, gene expression, and a complex trait, respectively 
investigated by identifying QTLs for the complex trait, ii) selecting gene expression traits 
correlated with the complex trait, iii) detecting eQTL, which overlap the identified QTL, for 
the selected expression traits; and iv) the likelihood based causality model selection (LCMS) 
test to identify the causal relationships of the genes detected with overlapping loci [Schadt et 
al., 2005].  
3. Two-step integrative analysis  
Schadt et al.‘s approah has two major limitations. First, although the filtering step is effective 
in reducing the search-space, it might result in more false negatives than exhaustive search 
approahes in detecting causal relationships of the genes, espeically when a true causal 
relationship exists based on the interaction effects among genotype, gene expression and a 
trait of interest, but any pairwise association is weak. Second, the model does not 
comprehensively handle the interaction effects, which might cause different disease 
susceptibility. Therefore Lee et al. proposed a two-step integrative approach handling with 
exhaustive search and interaction effects based on LCMS test [Lee et al., 2009]. In this section 
we provide a detailed review of the Lee et al.‘s two-step procedure integrating genotype 
data, gene expression and clinical data, and thus elucidating mechanisms underlying 
disease susceptibility and progression [Lee et al, 2009]. 
3.1 Introduction  
In figure 3, the two-step procedure is presented to illustrate the integration method based on 
causal relationship among the three different levels of data. In the first step, the most 
appropriate causality models are selected to understand the causal relationship among 
genetic variation, gene expression level, and disease for each gene expression-genetic 
variation combination. In the second step, significance testing is carried out based on a  
 
Fig. 3. Two-step procedure illustration of Lee et al.‘s. In the first step, for each gene 
expression-genetic variation combination, the most appropriate causality models are 
selected. Then in the second step, significance test is carried out based on a statistical model 
for each combination according to the model selected in previous step. 
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statistical model for each combination, such as logistic regression and a two-way analysis of 
variance (ANOVA), according to the causality model selected from the first step. Through 
these tests, gene expression traits whose effects on disease status or responses to disease 
status are modified by the genotype variation effects. 
3.2 The first step: Causality model selection 
The possible causal relationships among genetic variation, gene expression level and disease 
trait, can be summarized as three models. Figure 4 represents three simple models. Causal  
model assumes the simplest causal relationship with respect to mRNA expression, in which 
QTL acts on disease through transcript. Reactive model is the model with respect to mRNA 
expression, in which mRNA expression is modulated by disease. In independent model, 
QTL at a specific locus acts on these traits independently. 
Lee et al. assumed that each pair of genetic locus and expressed gene has one of these three 
simple causal relationships to examine potential relationships among the genotype 
variation, gene expression level and disease status. In order to find the most possible causal 
relation, both Lee et al. and Schadt et al. adapted the likelihood based causality model 
 
Fig. 4. Three possible causal relationships among genotype variation, mRNA level and 
complex disease proposed by Schadt et al. QTL, mRNA and disease represent any genotype 
variation like SNP, mRNA expression level of a gene, and complex disease or phenotype of 
interest, respectively. 
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selection (LCMS) test, which uses conditional correlation measures for determining the 
relationships best supported by the data. Unlike multistep procedure of Schadt et al.’s 
method, Lee et al. constructed likelihoods associated with each of the causality model and 
maximized with respect to the model parameters. Then, the best model was selected for 
each SNP-transcript combination, by choosing the model with the smallest Akaike 
Information Criterion (AIC) value which can be used to compare different models [Akaike, 
1974). 
Lee et al. and Schadt et al. both assumed standard Markov properties for the simple graphs 
(Fig. 4), the joint probability distributions for the three models are as follows: 
• Causal Model: PሺS, R, Dሻ = PሺSሻPሺR|SሻPሺD|Rሻ, 
• Reactive Model: PሺS, R, Dሻ = PሺSሻPሺD|SሻPሺR|Dሻ, 
• Independent Model: PሺS, R, Dሻ = PሺSሻPሺR|SሻPሺD|R, Sሻ, 
where S represents a genotype variation, R gene expression, and D disease status. P(S) is 
the genotype probability distribution for marker S and is further assumed to be co-
dominant. P(R|S) and P(R|D) are the conditional probabilities of R given genotypes S 
and disease status D, respectively. Lee et al. further assumed that the random variable R 
follows conditional normal distribution, and the random variable D has a binomial 
distribution. Therefore, in probability P(D|R), the random variable D has a binominal 
distribution with a success probability that can be modeled by a logistic regression model. 
P(D|S) is the probability distribution of D conditional on locus S, in which the random 
variable D also has a binomial distribution. Based on these assumptions, the likelihood of 
a correspondence to each of the joint probability distributions can be constructed. For 
each model, the model parameters can be estimated via a standard maximum likelihood 
method. The best model supported by the data is then chosen based on the AIC, which is 
commonly used to compare models with different numbers of parameters [Schadt et al., 
2005; Lee et al. 2009] 
3.3 The second step: Statistical test 
Step 2 performs statistical tests to determine the significance of the genetic regulatory 
relationships described in the causality model selected at step 1. The response and 
independent variables in the statistical models depend on the causality model selected at 
step 1. These statistical tests can deal with the interaction effects among the three different 
levels of data and to elucidate differences in disease susceptibility and gene expression 
pattern across genetically different individuals. The two-step procedure can result in a set of 
candidate causal and reactive genes, whose expressions affect disease status and respond to 
disease status under the influence of genotype variation, respectively. 
3.3.1 The causal model 
In order to investigate gene expression traits whose effects on disease status are modified by 
genotype variation, the interaction effect of genotype variation and gene expression level on 
the disease status can be examined using logistic regression below: 
 log itሺπሻ = S + R + S × R,  (1)   
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where π represents the probability of getting the disease; S represents the effect of genotype 
variation such as SNPs; R represents the effect of gene expression levels; and S × R 
represents the interaction effect between genotype variation and gene expression level. 
3.3.2 The reactive model 
For investigating gene expression traits whose responses to disease status are affected by 
genotype variations, one can fit the following two-way ANOVA model with the interaction 
between genotype variation and disease groups: 
 R = S + D + S × D,   (2) 
where S represents the effect of genotype variation; D represents the effect of disease 
groups; and S × D represents the interaction effect between genotype variation and disease 
groups. 
3.3.3 The independent model 
When the independent model is selected at step 1, the effect of genotype variation on each of 
gene expression and disease can be investigated separately. First, the logistic regression is 
employed to detect genotypic markers linked to disease loci: 
 log itሺπሻ = S.  (3) 
Next, it is possible to identify genotypic markers that regulate gene expression levels, based 
on the one-way ANOVA model where the dependent variable is R and the independent 
variable is S. 
In step 2, significant associations among genotype variation, gene expression and disease 
status are declared via statistical tests for all possible pairs of gene expression-genotype 
variation. Due to the large number of tests, the multiple-testing problem needs to be 
addressed. In order to adjust this multiplicity, Lee et al. used a step-up procedure controlling 
false discovery rate (FDR) [Benjamini & Hochberg, 1995]. 
4. Application 
Lee et al. applied their two-step procedure to chronic fatigue syndrome (CFS) data to 
elucidate a list of potential causal genes of CFS. In this section, we provide the application of 
two-step procedure of Lee et al.’s 
4.1 Chronic Fatigue Syndrome (CFS) dataset 
Chronic fatigue syndrome (CFS) is a debilitating illness lacking consistent anatomic lesions 
and eluding conventional laboratory diagnosis. CFS has no confirmatory physical signs or 
laboratory abnormalities, and its etiology and pathophysiology are unknown. This disease 
characterized by chronic fatigue, lasting at least 6 months, which is accompanied by 
symptoms such as impairment in short-term memory or concentration, sore throat, tender 
lymph nodes, and muscle pain. The Centers for Disease Control and Prevention (CDC) 
Chronic Fatigue Syndrome Research Group produced the dataset including gene expression 
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of 177 subjects, proteomic of 60 subjects, single nucleotide polymorphism (SNP) of 50 
subjects, and clinical data of 227 subjects. All the data set is available on the following web 
site (http://www.camda.duke.edu/camda06/datasets/index.html). 
According to severity of symptoms, the patients were originally classified into five groups 
of CFS. Lee et al.’s study, however, only consider three groups of total 101 subjects: 46 
subjects meeting the CFS research case definition (CFS), 19 subjects meeting the CFS 
research case definition and having ‘a major depressive disorder with melancholic features’ 
(CFS-MDD/m), and 36 subjects who show no fatigue (NF). 
This CFS dataset has been analysed by many research groups for identifying molecular 
markers and elucidating pathophysiology of CFS, for finding two differentially expressed 
genes related with fatigue and depression, respectively, for discriminating classes of 
unexplained chronic fatigue based on differential gene expressions, and for examining the 
relationship between CFS and allostatic load based on the clinical dataset. In the CFS 
dataset, the expression levels of 20,160 genes were assessed from peripheral blood 
mononuclear cells, via custom-printed single-channel oligonucleotide chips. Quantile 
normalization was conducted on the gene expression data which were pre-processed by the 
original CDC research group. For genotype data, the whole blood DNA was extracted and 
specific areas of the genes of interest were amplified by PCR.  
For illustration, we summarized the analyses results from the multi-step procedure of 
Schadt et al. and the two-step approach of Lee et al. The detailed description of the results is 
provided in Lee et al. [Lee et al., 2009]. 
4.2 Results 
4.2.1 Multi-step procedure by Schadt et al. 
The multi-step procedure proposed by Schadt et al. was applied to the same datasets for the 
purpose of comparison. First, a gene expression analysis was carried out to detect 
differentially expressed genes across clinical outcomes. Only a few genes were identified as 
differentially expressed (Table 1A) by three commonly used approaches such as the t-test, 
significance analysis of microarray (SAM) [Tusher et al., 2001] and the Bayesian regression 
approach [Baldi & Long, 2001]. Second, genotype variation data and clinical outcomes were 
analyzed via logistic regression to detect the susceptibility genes of disease. Out of all 41 
markers tested, nine markers were detected with significant genotype effect on initiation of 
CFS at a 5% significance level, while only four markers were detected with 5% FDR 
[Benjamini & Hochberg, 1995] (Table 1B). Interestingly, different sets of susceptible genes 
were identified as having statistically significant association with CFS and CFS-MDD/m. 
From the CFS vs. NF comparison, the seven markers in the NR3C1 gene were identified as 
significant markers linked to CFS. On the other hand, the CFS-MDD/m vs. NF comparison 
revealed the two significant markers in the COMT gene. Finally, for each of the differentially 
expressed genes across clinical outcomes, eQTL were searched at each of the markers that 
were identified at the second step, via one-way ANOVA of genotype variation and gene 
expression data. No significant association between gene expression level and genotype 
variation was found for any genotype–gene expression combination at a 5% significant 
level.  
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Dataset t-test SAM test Bayesian model   
A. Number of genes with significant change in expression levels over different disease 
status, which were detected via t-test, SAM test and Bayesian model. 
CFS vs. NG 1 2 0
CFS-MDD/m 
vs. NF 
1 1 0   
   
Gene SNPa Chromosome Position(Mb)b 
CFS vs. 
NF 
CFS-MDD/m 
vs. NFc 
B Significant genotype variation linked to disease loci, which were detected via logistic 
regression 
NR3C1e rs2918419 5 142.641 0.0104 0.3950 
 rs1866388 5 142.702 0.0010f 0.0472 
 rs860458 5 142.739 0.0104 0.3950 
 rs852977 5 146.642 0.0035f 0.1878 
 rs6196 5 146.660 0.0208 0.6423 
 rs6188 5 146.667 0.0027f 0.0396 
 rs258750 5 146.674 0.0035f 0.1009 
COMTg rs933271 22 18.311 0.0649 0.0025 
 rs5993882 22 18.317 0.4306 0.0114 
Table 1. parallel analyses for respective association of gene expression and genotype 
variation with disease status (by courtesy of the authors) [Lee et al., 2009] 
As multiple filtering steps is Schadt et al.’s procedure, the separate analyses were conducted 
respectively on two datasets, CFS vs. NF groups and CFS-MDD/m vs. NF groups. Bold numbers 
indicate p-values < 0.05. 
a NCBI dbSNP Build number is 125 using Human Genome Build 35.1 
b Position of SNP on chromosome.1 
c p-value from logistic regression with CFS vs. NF data. 
d p-value from logistic regression with CFS-MDD/m vs. NF data. 
e Glucocorticoid receptor located at 5q34. 
f Significant at the 5% false discovery rate (FDR). 
g Catechol-O-methyltransferase located at 22q11.1. 
In other words, no significant results were detected for both datasets from the Schadt et al.'s 
multi-step method. 
4.2.2 Two-step integrative analysis 
Lee et al. analyzed each combination of 20,160 genes and 41 SNPs with their two-step 
integrative analysis on two datasets, CFS vs. NF groups and CFS-MDD/m vs. NF groups. 
For each gene–SNP combination, the best causal relationship was detected via the causality 
model selection at step 1. In comparing CFS with NF groups, the reactive model was 
selected for ∼70% of 20,160 genes on average, for all nine markers within two known CFS-
related genes, such as NR3C1 and COMT (Table 2). However, in comparing CFS-MDD/m 
with NF groups, the causal model was selected for nearly 70% genes for three markers in the 
NR3C1 gene. This different tendency in the model selection results between CFS and CFS-
MDD/m would imply different genetic mechanisms of CFS and CFS-MDD/m. 
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At step 2, each gene–SNP combination data was analyzed based on one of the three 
statistical models, corresponding to the detected causal relationship. For all seven SNPs 
within NR3C1, significant causal relationships with gene expression levels were detected for 
either or both datasets (Table 2). Three SNPs (rs258750, rs6188 and rs852977) showed 
significant relationships with expression levels of a large number of genes, and can be 
candidates for genetic modulators of CFS- related regulatory pathways. 
Gene SNP CFS vs. NF CFS-MDD/m vs. NF 
Causala Reactiveb Independentc Causala Reactiveb Independentc 
NR3C1d Rs2918419 0 (639) 7 (16,215) 0 (3306) 8 
(13,955)
3 
(5912) 
0 (293) 
 Rs1866388 0 (165) 0 (16,872) 0 (3123) 15 
(4136) 
71 
(15,976) 
0 (48) 
 Rs860458 0 (639) 7 (16,215) 0 (3306) 8 
(13,955)
3 
(5912) 
0 (293) 
 Rs852977 0 (230) 0 (17,001) 0 (2929) 120 
(9760) 
73 
(10,139) 
0 (261) 
 Rs6196 0 (604) 2 (15,037) 0 (4519) 0 
(16,278)
0 
(2013) 
0 (1869) 
 Rs6188 0 (171) 7 (16,970) 1 (3019) 52 
(2939) 
217 
(17,074) 
0 (147) 
 Rs258750 0 (242) 0 (16,279) 105 (3639) 0 (2769) 14 
(12,590) 
0 (4801) 
COMTe Rs933271 0 (1943) 0 (15,156) 0 (3061) 0 (169) 0 (16,872) 0 (3119) 
 Rs5993882 0 (1022) 0 (14,380) 0 (4758) 0 (547) 0 (17,333) 0 (2280) 
Table 2. Two-step integration based on causality model selection. (by courtesy of the 
authors) [Lee et al., 2009] 
The integrative analyses were conducted respectively on two datasets, CFS vs. NF groups and CFS-
MDD/m vs. NF groups. Note that the results are presented only for nine SNPs within two known CFS-
related genes (NR3C1 and COMT). For each combination of 20,160 genes and 41 SNPs, the best causal 
relationship was detected via causal model selection at step 1. Numbers in parenthesis indicate the 
numbers of genes having each causal relationship with each SNP and disease status. At step 2, each 
gene-SNP combination data was analyzed based on one of the three statistical models, corresponding to 
the detected causal relationship. Outside parenthesis, we present the numbers of significant genes 
identified by the corresponding statistical models. Three SNPs, each of which involves significant causal 
relationships with expression levels of more than 100 genes, are marked in bold. 
a Logistic regression was conducted to identify genes whose expressions have interaction effect with 
genotype variation on disease status. 
b Two-way ANOVA was conducted to identify genes whose expressions are affected by interaction 
between genotype variation and disease status. 
c Independent test was conducted to identify genes whose expressions differ according to SNP 
genotypes. 
d Gluccorticoid receptor located at 5q34. 
e Catechol-O-methltransferase located at 22q11.1. 
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Next, pathway enrichment analyses were performed for these three SNPs, and the results 
are given in the next section. In comparing CFS with NF groups, for the rs258750 marker, 
105 genes were identified with differential expression across genotypes with 5% FDR from 
the independent test. This result is supported by the evidence of the neuroendocrine 
regulation of immunity, because the gene expression data were obtained from a 
mononuclear cell, and the role of glucocorticoid receptor (NR3C1) gene is to regulate the 
level of glucocorticoid. 
In the integrated analysis for comparing CFS-MDD/m with NF groups, for the rs6188 
marker in the NR3C1 gene, 52 genes showed significant interaction effects with the rs6188 
marker on disease status CFS-MDD/m from the logistic regression model. Also, the two-
way ANOVA models yielded 217 candidate reactive genes, on which there are significant 
interaction effects between disease status and genotypes. Note that these candidate genes, 
especially reactive genes, could not be detected by Schadt et al.'s method. The Lee et al.'s 
two-step integration method revealed the causal association among gene expression level, 
genotype and disease status in depth. Candidate causal/reactive genes were detected also 
for rs852977 in the NR3C1 gene. However, the candidate gene set for the rs852977 is very 
similar to that for the rs6188, with slight differences in causality structure. This similarity 
would be due to a strong linkage between the two SNPs. 
4.2.3 Pathway enrichment analysis 
In comparing CFS with NF groups, Lee et al. further conducted a pathway enrichment analysis 
for 105 genes that were identified to have a significant relationship with the rs258750 marker 
from the independent test at step 2. The pathway classification showed that nine different 
pathways were associated with the rs258750 marker at the 5% significance level (Table 3). Out 
of nine pathways, four were enriched with genes involved in regulation of transcription, 
translation or mRNA processing, and three are related with immune system. 
For comparing CFS-MDD/m with NF groups, pathway enrichment analyses were 
conducted on the genes that were identified to have a significant relationship with the 
rs6188 and/or rs852977 markers at step 2. Because of the linkage between the two SNPs, the 
results were similar (Tables 4 and 5), and the results was given only for the rs6188. While 
seven different pathways were detected at the 5% significance level for the 52 candidate 
causal genes, eleven different pathways were detected for the 217 candidate reactive genes 
(Table 4). In addition, two other pathways, whose p-values were slightly larger than the 5% 
significance level, are listed. 
In pathway enrichment analyses of the candidate causal genes, the steroid biosynthesis 
pathway appears to have a direct causal effect on the disease status, CFS-MDD/m, through 
an integrative action of the rs6188 marker within the NR3C1 gene. The two significantly 
enriched biological pathways (i.e., ‘IL-2 Receptor Beta Chain in T cell Activation’, and ‘HIV-
1 Nef: negative effector of FAS and TNF’) are all related to the immune system. On the other 
hand, the pathway enrichment analysis of the candidate reactive genes showed that several 
pathways related to lipid metabolism or biosynthesis, such as eicosanoid and fatty acid, 
appear to be important for responding to CFS-MDD/m. Furthermore, other pathways 
associated with neuron physiology and neurotransmitters appear to respond to CFS-
MDD/m. 
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Pathwaya Modelb Sourcec Nodesd Gene ID e Gene name 
Galactose 
metabolism 
Indepe-
ndent 
KEGG 2/22 B4GALT2
MGAM 
UDP-Gal:betaGlcNAc beta 
1,4-galactosyltransferase, 
polypeptide2 
Maltase-glucoamylase 
Basic 
mechanisms of 
SUMOylation 
Indepe-
ndent 
BioCarta 1/4 SUMO3 SMT3 suppressor of mif two 3 
homolog 3 
Internal 
ribosome entry 
pathway 
Indepe-
ndent 
BioCarta 1/8 EIF4E Eukaryotic translation 
initiation factor 4E 
Neutrophil and 
its surface 
molecules 
Indepe-
ndent 
BioCarta 1/8 ITGB2 Integrin, beta 2 
Alternative 
complement 
pathwy 
Indepe-
ndent 
BioCarta 1/9 CFB Complement factor B 
Mechanisms of 
protein import 
into the nucleus 
Indepe-
ndent 
BioCarta 1/9 NUP62 Nucleoporin 62kDa 
Polyadenylation 
of mRNA 
Indepe-
ndent 
BioCarta 1/9 PABP2 Poly(A) binding protein II 
B Lymphocyte 
cell surface 
molecules 
Indepe-
ndent 
BioCarta 1/9 ITGB2 Integrin, beta 2 
Adhesion 
molecules on 
lymphocyte 
Indepe-
ndent 
BioCarta 1/9 ITGB2 Integrin, beta 2 
Table 3. Significant regulated pathways for SNP rs258750 (by courtesy of the authors) [Lee et 
al., 2009] 
Pathway enrichment analysis was conducted using 105 candidate independent genes, which 
were identified for rs258750. Significant biological pathways were detected via Fisher’s exact 
test at a 5% significance level. Pathways are listed in order of significance e.g., most 
significant pathway presents at the top. 
a Name of biological pathway selected by Fisher’s exact test. 
b Causality models selected ay step1. 
c Source of pathway 
d The number of candidate causal/reactive genes associated with pathway/the number of 
all genes associated with pathway. 
e Gene ID of candidate genes associated with pathway 
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Pathwaya Modelb Sourcec Nodesd Gene ID e Gene name 
Electron transport 
chain 
Causal GenMapp 2/105 COX11 
COX6A1 
Cytochrome c oxidase 
subunit11 
Cytochrome c oxidase 
subunit Via polypeptide 1  
Steroid 
biosynthesis 
Causal GenMapp 1/9 F13B Coagulation factor XIII,B 
polypeptide 
Blood clotting 
cascade 
Causal GenMapp 1/19 F13B Coagulation factor XIII,B 
polypeptide 
FAS signaling 
pathway(CD95) 
Causal BioCarta 1/30 CFLAR CASP8 and FADD-like 
apoptosis regulator 
Induction of 
apoptosis through 
DR3 and DR4/5 
Death Receptor 
Causal BioCarta 1/32 CFLAR CASP8 and FADD-like 
apoptosis regulator 
IL-2 receptor beta 
chain in T cell 
activation 
Causal BioCarta 1/35 CFLAR CASP8 and FADD-like 
apoptosis regulator 
HIV-1 Nef:negative 
effector of FAS and 
TNF  
Causal BioCarta 1/57 CFLAR CASP8 and FADD-like 
apoptosis regulator 
Agrin in 
postsynaptic 
differentiation 
Reactive BioCarta 3/39 UTRN 
DVL1 
ARHGEF6
Utrophin 
Dishevelled,dsh 
homolog1 
Rac/Cdc42 guanine 
nucleotide exchange 
factor(GEF)6 
Cell cycle Reactive GenMapp 4/87 CDC14A 
E2F2 
CDC20 
CDC14 cell division cycle 
20homolog 
E2F transcription factor2 
CDC20 cell division cycle 
20homolog 
Eicosanoid 
metabolism 
Reactive BioCarta 2/20 PTGES 
EPHX1 
Prostaglandin E synthase 
Epoxide hydrolase 
Biosyntheisis of 
cysteine  
Reactive BioCarta 1/2 CBS Cystathionine-beta-
synthase 
Biosyntheisis of 
threonine and 
methionine  
Reactive BioCarta 1/2 CBS Cystathionine-beta-
synthase 
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Pathwaya Modelb Sourcec Nodesd Gene ID e Gene name 
Inactivation of 
Gsk3 by  
AKT causes 
accumulation  
of β-catenin  
in alveolar 
macrophages 
Reactive BioCarta 2/25 MYD88
DVL1 
Myeloid differentiation 
primary response gene 
(88) 
Disheveled, 
dsh homolog 1 
Fatty acid 
metabolism 
Reactive KEGG 3/57 HADHB Hydroxyacyl-Coenzyme 
A dehydrogenase/3-
ketoacyl-Coenzyme 
A thiolase/enoyl-
Coenzyme A hydraatase, 
beta subunit 
Bile acid 
biosynthesis 
Reactive KEGG 2/26 ADH6 Alcohol dehydrogenase 6 
(class V)  
Catabolic  
pathways for 
methionine,isoleuci
ne,threonine 
And valine 
Reactive BioCarta 1/4 CBS Cystathionie-beta-
synthase 
Basic mechanisms 
of SUMOylation
Reactive BioCarta 1/4 SMT3H1 SMT3 suppressor of  
mif two 3 homolog 3 
ALK in cardiac 
myocytes 
Reactive BioCarta 2/34 DLV1
CHRD
Chordin
Taurine and 
hypotaurine 
metabolismf 
Reactive KEGG 1/5 GAD1 Glutamate 
decarboxylase 1 
Biosynthesis of 
neurotransmittersf 
Reactive BioCarta 1/6 GAD1 Glutamate 
decarboxylase 1 
Table 4. Significant regulated pathways for SNP rs6188 (by courtesy of the authors) [Lee et 
al., 2009] 
Pathway enrichment analysis was conducted using 52 candidate causal genes and 217 candidate 
reactive genes, which were identified for rs6188. Significant biological pathways were detected via 
Fisher’s exact test at a 5% significance level. Pathways are listed in order of significance within each of 
causality models, e.g., most significant pathway presents at the top. 
a Name of biological pathway selected by Fisher’s exact test. 
b Causality models selected ay step1. 
c Source of pathway 
d The number of candidate causal/reactive genes associated with pathway/the number of all genes 
associated with pathway. 
e Gene ID of candidate genes associated with pathway. 
f Pathways with p-value that is slightly larger than 0.05. 
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Pathwaya Modelb Sourcec Nodesd Gene ID e Gene name
Agrin in 
postsynaptic 
differentiation 
Causal BioCarta 2/39 DMD
DVL1 
Dystrophin
Dishevelled,  
dsh homolog 1 
Steroid 
biosynthesis 
Causal Gen
MAPP 
1/9 F13B Coagulation factor XIII, B 
polypeptide 
Nucleotide 
GPCRs 
Causal Gen
MAPP 
1/10 P2RY4 Pyrimidinergic receptor P2Y, 
G-protein coupled 4 
RNA 
polymerase III 
transcription 
Causal BioCarta 1/8 GTF3C1 General transcription factor 
IIIC, polypeptide 1,  
alpha 220kDa 
Blood clotting 
cascade 
Causal Gen
MAPP 
1/19 F13B Coagulation factor XIII,  
B polypeptide 
Bile acid 
biosynthesis 
Causal KEGG 1/26 ADH6 Alcohol dehydrogenase 6 
Tyrosine 
metabolism 
Causal KEGG 1/37 ADH6 Alcohol dehydrogenase 6I 
Inactivation of 
Gsk3 by AKT 
causes 
accumulation of 
b-catenin in 
alverolar 
macrophages 
Reactive BioCarta 1/25 MYD88
DVL1 
Myeloid differentiation 
primary response gene (88) 
Dishevelled, dsh homolog 1 
ALK in cardiac 
myocytes 
Reactive BioCarta 1/34 DVL1
CHRD 
Dishevelled, dsh homolog 1 
Chordin 
Biosynthesis of 
neurotransmitter
Reactive BioCarta 1/6 GAD1 Glutamate decarboxylase 1 
Taurine and 
hypotaurine 
metabolism 
Reactive KEGG 1/5 GAD1 Glutamate decarboxylase 1 
Electron 
transport chain 
Reactive Gen
MAPP 
2/105 COX11
COX6A1 
Cytochrome c oxidase 
subunit 11 
Cytochrome c oxidase 
subunit Vla polypeptide 1 
Table 5. Significant regulated pathways for SNP rs852977 (by courtesy of the authors) [Lee et 
al., 2009] 
Pathway enrichment analysis was conducted using 120 candidate causal genes, which were identified 
for rs852977. Significant biological pathways were detected via Fisher’s exact test at a 5% significance 
level. Pathways are listed in order of significance within each of causality model, e.g., most significant 
pathway presents at the top. 
a Name of biological pathway selected by Fisher’s exact test. 
b Causality models selected ay step1. 
c Source of pathway 
d The number of candidate causal/reactive genes associated with pathway/the number of all genes 
associated with pathway. 
e Gene ID of candidate genes associated with pathway. 
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5. Discussion 
The two-step procedure can integrate gene expression data, genotype variation data and 
clinical data, and identify the genetic mechanism of a complex disease. We described three 
different statistical tests based on the two-step procedure proposed by Lee et al.. For 
purposes of comparison, two different CFS related datasets were analyzed via the multi-step 
procedure proposed by Schadt et al.. In these specific datasets, no significant results were 
detected from the multistep method of Schadt et al., while the method of Lee et al. enabled 
us to identify many statistically significant causal relationships, some of which were 
biologically supported by pathway enrichment analyses. These results demonstrated that 
the two-step method based on an exhaustive search investigation would provide more 
power. 
Furthermore, the two-step approach provided some interesting results. First, CFS groups 
and CFS-MDD/m groups would appear to have different genotypes and gene expression 
profiles even though they had the common characteristic of chronic fatigue. In particular, 
CFS has major susceptibility markers within the NR3C1 gene, and CFSMDD/m seems to 
have major susceptibility markers within the catechol-O-methyltransferase (COMT) gene, 
though they are not statistically significant after FDR correction (Table 1B). The NR3C1 gene 
regulates the level of glucocorticoid which is the end product of the hypothalamic-pituitary-
adrenal (HPA) whereas COMT catalyzes the transfer of a methyl group from S-
adenosylmethionine to catecholamines, which is the principal end product of the 
sympathetic nervous system (SNS), of which the role is maintaining stress-related 
homeostasis [Elenkov et al., 2000]. The different major susceptibility gene may be related 
with to the provoking of MDD/m. 
Second, polymorphisms in the glucocorticoid receptor NR3C1 gene act on CFS and CFS-
MDD/m differently. The polymorphisms (rs258750) within NR3C1 have significant effects 
on CFS, and the 105 gene expression levels independently. However, in the integrated 
analysis for comparing CFS-MDD/m and NF groups, polymorphisms within the NR3C1 
gene affect the CFS-MDD/m and several gene expression levels differently. For example, 
the 217 genes are differentially expressed according to the rs6188 marker genotype within 
NR3C1 and disease status, even though polymorphisms within NR3C1 have no direct 
significant effects after FDR correction on the CFS-MDD/m. In addition, the 52 genes also 
regulate the CFS-MDD/m, through integrated action with the rs6188 marker. The different 
action of the NR3C1 gene on gene expression level and disease may be an outcome of other 
factors, such as environmental effects or polymorphisms of the COMT gene. The 
catecholamines which are regulated by the COMT gene, have been often been regarded as 
immunosuppressive [Elenkov et al., 2000]. 
Two pathway enrichment analyses for the 52 candidate causal genes and 217 candidate 
reactive genes indicated that our approach can recover plausible regulatory mechanisms of 
CFS-MDD/m by comparing CFS-MDD/m and NF groups. From the comparison, we 
noticed that the pathways related to the immune system and steroid may have causal effect 
on disease state through an integrative action of the NR3C1 gene. Both the NR3C1 gene that 
regulates the level of glucocorticoid, and the steroid that includes corticosteroids are known 
to regulate the immune function [Webster et al., 2002]. A number of studies have found 
many irregularities in the immune systems in CFS patients [Natelson et al., 2002]. This 
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suggested that an important cause of CFS-MDD/m would be the immune system 
dysfunction, regulated by the neuroendocrine system, which rs6188 in the NR3C1 gene 
seems influence. Another potential implication of this comparison is that the CFS-MDD/m 
status and genetic polymorphisms can jointly induce different activation and expression of 
several lipid related metabolisms, neuron physiology differentiation, and neurotransmitters. 
Our results are supported by the known relationship between eicosanoid or fatty acid and 
CFS [Grey & Martinovic, 1994; Puri, 2007; Puri et al., 2004; Liu et al., 2003]. 
However, since fatigue is a core symptom in major depressive disorder [Pae et al., 2007], 
CFS-MDD/m patients might have fatigue due to the depression rather than unexplained 
causes, and hence the significant results may be related to a ‘major depression disorder with 
melancholic features’ rather than chronic fatigue. For example, the excessive hypothalamus-
pituitary-adrenal (HPA) axis responses, of which the end products are glucocorticoids, are 
known to be hallmarks of depression [Pariante & Miller, 2001; Holsboer, 2000; Pariante, 
2004]. Also, the major depression can be associated with the immune activation, dysfunction 
of neurotransmitters at synapse [Neumeister et al., 2004; Sanacora et al., 2004; Maes & 
Meltzer, 1995], and essential fatty acids [Van Strater & Bouvy, 2006]. 
The integrative analyses considering the interaction effect among different levels of data 
could elucidate different disease susceptibility and differentially expressed genes of 
genetically different individuals. Some results showed that integrating genotype and 
expression data may help the search for new directions for the treatment of common human 
diseases that are not being detected using only one type of data. The integrated analysis 
provided more information than the two separate analyses of gene expression data and 
genotype variation data for characterizing CFS that has several possible causes. 
In conclusion, the two-step approach to the integration of heterogeneous data sets can be 
generally applied to other studies in which gene expression data, genotype variation data 
and clinical data are available, and it can be very useful as the importance of integrated data 
analysis has been increasing. The two-step approach can also be extended to datasets 
containing other type of data, such as protein data rather than clinical data. The two-step 
approach can be readily applicable to quantitative traits rather than binary clinical outcome 
traits, by employing linear regression analysis. Also, it can be easily applied to genome-wide 
association studies, and can handle environmental factors, such as age and sex, by treating 
these factors as covariates in the regression model. Furthermore, the two-step approach can 
be extended to the gene-set approach, the module based approach or co-expression network 
as Presson et al. [Presson et al., 2008] and Chen et al. [Chen et al., 2008] did. 
However, there are some limitations to the two-step method. First, the causality models are 
too simple to represent true mechanisms, which would be more complicated due to possible 
interactions between causal-reactive genes [Schadt et al., 2005]. Further considerations for 
more complicated models are necessary in order to identify the genetic mechanism of 
complex diseases. Second, the two-step approach may need large computing although it is 
applicable to genome-wide studies because it is not limited in the scale of data. Another 
limitation would be a misclassification problem in that the proposed method relies on the 
LCMS. The current two-step approach does not use FDR procedure to account for the model 
misclassification problem. In fact, FDR procedure was employed only in the second step, not 
in the first step for the model selection procedure that chooses the model with the minimum 
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AIC among the three causal models. While anticipating the problem, we still employed the 
LCMS process because it showed good power for detecting true models in the simulation 
evaluated by Schadt et al. The two-step approach can be extended to account for the errors 
caused by the model misclassification in the first step. For example, we can test for the 
difference in the AIC values of three causality models, because the chance for model 
misclassification would be high when the difference between the smallest AIC value from 
the selected model and those from the other models is not large. A permutation-based 
nonparametric test might be developed for this testing. We think it requires a further study 
to control simultaneously two types of errors: causality model selection, and significant 
maker-gene pair identification.  
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